...At least two other P-CABs are also in the clinic for GERD: tegoprazan (RQ-04) from RaQualia Pharma Inc.... ...Daewoong Pharmaceutical Co. Ltd. (KSE:069620), Seoul, South Korea Jiangsu Sinorda Biomedicine Co. Ltd., Suzhou, China RaQualia Pharma Inc....
...Osaka, Japan) exclusive, worldwide rights to develop and commercialize an undisclosed selective sodium channel blocker. RaQualia... ...disclose details. RaQualia Pharma Inc. (JASDAQ:4579), Nagoya, Japan Maruho Co. Ltd., Osaka, Japan Business: Neurology
Chris Lieu
Maruho Co. Ltd.
RaQualia Pharma Inc....
...develop potential clinical applications of induced pluripotent stem (iPS) cells. 11/18/2015 RaQualia Pharma Inc. (JASDAQ:4579) Nagoya University RaQualia...
...pain compounds targeting an undisclosed ion channel. The partners will use RaQualia’s drug development technology. RaQualia... ...BioCentury, Nov. 25, 2013 & April 14, 2014). Asahi Kasei Pharma Corp. , Tokyo, Japan RaQualia Pharma Inc....
...structure-based drug discovery platforms to design therapeutics targeting protein-protein interactions. In 2013, it partnered with RaQualia Pharma Inc....
...to regain Japanese rights to dalbavancin from Allergan plc (NYSE:AGN, Dublin, Ireland). In December 2010, RaQualia... ...skin structure infections (ABSSSIs) in adults (see BioCentury, May 2, 2011 & Nov. 24, 2014). RaQualia Pharma Inc....
...At least two other P-CABs are also in the clinic for GERD: tegoprazan (RQ-04) from RaQualia Pharma Inc.... ...Daewoong Pharmaceutical Co. Ltd. (KSE:069620), Seoul, South Korea Jiangsu Sinorda Biomedicine Co. Ltd., Suzhou, China RaQualia Pharma Inc....
...Osaka, Japan) exclusive, worldwide rights to develop and commercialize an undisclosed selective sodium channel blocker. RaQualia... ...disclose details. RaQualia Pharma Inc. (JASDAQ:4579), Nagoya, Japan Maruho Co. Ltd., Osaka, Japan Business: Neurology
Chris Lieu
Maruho Co. Ltd.
RaQualia Pharma Inc....
...develop potential clinical applications of induced pluripotent stem (iPS) cells. 11/18/2015 RaQualia Pharma Inc. (JASDAQ:4579) Nagoya University RaQualia...
...pain compounds targeting an undisclosed ion channel. The partners will use RaQualia’s drug development technology. RaQualia... ...BioCentury, Nov. 25, 2013 & April 14, 2014). Asahi Kasei Pharma Corp. , Tokyo, Japan RaQualia Pharma Inc....
...structure-based drug discovery platforms to design therapeutics targeting protein-protein interactions. In 2013, it partnered with RaQualia Pharma Inc....
...to regain Japanese rights to dalbavancin from Allergan plc (NYSE:AGN, Dublin, Ireland). In December 2010, RaQualia... ...skin structure infections (ABSSSIs) in adults (see BioCentury, May 2, 2011 & Nov. 24, 2014). RaQualia Pharma Inc....